Chronic heart failure, chronic kidney disease (stages 3–4), type 2 diabetes, atherosclerotic cardiovascular disease (coronary heart disease, ischemic stroke, peripheral artery disease)
Conditions
Interventions
Non-SGLT2i Control Group:NA
SGLT2 Inhibitor Group:NA
Sponsors
Xi'an Jiaotong University Second Affiliated Hospital
Eligibility
Sex/Gender
All
Age
80 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=80 years at the index date. 2. Meet the definition of "multiple comorbidities": The patient must have been clinically diagnosed with >=2 diseases from the following core chronic disease list during the index hospitalization, with at least one being the primary reason for this hospitalization or directly related to decompensation: Type 2 diabetes (currently receiving glucose-lowering treatment or HbA1c >=7.0%) Chronic heart failure (NYHA class II–IV, or with recent evidence of decompensation) Chronic kidney disease (CKD stages 3–4, baseline eGFR 25–90 mL/min/1.73m²) Atherosclerotic cardiovascular disease (coronary heart disease, ischemic stroke, peripheral artery disease); 3. Hospitalization due to acute decompensation or complications of diseases listed above, and discharged alive. 4. During this hospitalization or at discharge, newly prescribed any SGLT2 inhibitor (SGLT2i group), or not prescribed an SGLT2i but receiving guideline-recommended standard treatment for the primary diagnosis (control group). 5. Baseline eGFR >=25 mL/min/1.73m².
Exclusion criteria
Exclusion criteria: 1. Any use of SGLT2 inhibitors within 365 days prior to the index date. 2. Type 1 diabetes mellitus. 3. End-stage renal disease at the index date (eGFR <15 mL/min/1.73m² or receiving renal replacement therapy). 4. Life expectancy <3 months at the index date. 5. Key information in the medical records (such as discharge medications and primary endpoints) is severely missing, making it impossible to assign groups or determine endpoints.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite cardiorenal outcome occurring within one year after discharge.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite safety endpoint;Medication patterns; | — |
Countries
China
Contacts
Public ContactGaigai Ma
Xi'an Jiaotong University Second Affiliated Hospital
Outcome results
None listed